Home - Australian Pharmacist

Stye no more: a practical guide for management

Hui Wen Quek and Amy Page PhD FPS - November 6, 2000

CPD

References Sun M, Huang S, C Huilgol S, et al. Eyelid lesions in general practice. Aust J Gen Pract 2019;48:509–14. Australian Medicines Handbook. Eye...

‘Can I have Rikodeine for my next dry cough?’

Peter Guthrey FPS - November 20, 2000

Clinical

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines ACT3 No comparable criteria NSW4 · pharmacist gives the person an opportunity to seek advice as...

Whitfield’s ointment

AP Staff - October 9, 2000

Clinical

Homei A, Worboys M. Fungal Disease in Britain and the United States 1850–2000: Mycoses and Modernity. Chapter 2: Athlete’s foot: a disease of...

References Cancer Council Australia. Skin cancer incidence and mortality 2025. At: www.cancer.org.au/about-us/policy-and-advocacy/prevention/uv-radiation/related-resources/skin-cancer-incidence-and-mortality Cancer Council NSW. About skin cancer. 2024. At: www.cancercouncil.com.au/skin-cancer/about-skin-cancer/#common Serrels, Mark. We...

Summer of fun?

AP Staff - November 28, 2000

Advertorial

RB - October 31, 2000

What's changing?

When do the changes take effect?

What's the concern about vitamin B6?

How many products are affected?

Will there be any other changes for vitamin B6 products?

How will patients be informed of these changes?

References

What’s driving this impairment?

What should pharmacists do?

What are the next steps?

National guidance, local implementation

Recognising high risk patients

Safer care from the moment of admission

Preparing for discharge

Better communication when systems aren’t interoperable

The valuable role of GP and aged care pharmacists

Why is the CPD accreditation system changing?

What can pharmacists expect from PSA accredited CPD activities?

With the impending changes to CPD, will I need to do anything differently?

Can I still complete CPD activities accredited against the APC CPD Accreditation standards?

Will CPD activities still be worth the same number of credits?

Can I still use the PSA CPD Planning Tool?

How far along is PSA in finalising the CPD standards?

What’s the feedback on PSA’s draft standards document so far?

Where can I access more information?

Flag 1. A carer blurs professional boundaries

Flag 2. An unsafe or non-compliant compounding request

Flag 3. Cultural safety blindspots

Flag 4. Medicinal cannabis scripts where products, dosing and evidence

Flag 5. Unusual doses of high-risk medicines

What's changing?

When do the changes take effect?

What's the concern about vitamin B6?

How many products are affected?

Will there be any other changes for vitamin B6 products?

How will patients be informed of these changes?

References

What’s driving this impairment?

What should pharmacists do?

What are the next steps?

National guidance, local implementation

Recognising high risk patients

Safer care from the moment of admission

Preparing for discharge

Better communication when systems aren’t interoperable

The valuable role of GP and aged care pharmacists

Why is the CPD accreditation system changing?

What can pharmacists expect from PSA accredited CPD activities?

With the impending changes to CPD, will I need to do anything differently?

Can I still complete CPD activities accredited against the APC CPD Accreditation standards?

Will CPD activities still be worth the same number of credits?

Can I still use the PSA CPD Planning Tool?

How far along is PSA in finalising the CPD standards?

What’s the feedback on PSA’s draft standards document so far?

Where can I access more information?

Flag 1. A carer blurs professional boundaries

Flag 2. An unsafe or non-compliant compounding request

Flag 3. Cultural safety blindspots

Flag 4. Medicinal cannabis scripts where products, dosing and evidence

Flag 5. Unusual doses of high-risk medicines

What's changing?

When do the changes take effect?

What's the concern about vitamin B6?

How many products are affected?

Will there be any other changes for vitamin B6 products?

How will patients be informed of these changes?

References

What’s driving this impairment?

What should pharmacists do?

What are the next steps?

National guidance, local implementation

Recognising high risk patients

Safer care from the moment of admission

Preparing for discharge

Better communication when systems aren’t interoperable

The valuable role of GP and aged care pharmacists

Why is the CPD accreditation system changing?

What can pharmacists expect from PSA accredited CPD activities?

With the impending changes to CPD, will I need to do anything differently?

Can I still complete CPD activities accredited against the APC CPD Accreditation standards?